Early-Stage Allegro Diagnostics Prepares For Gene Array Market Entry
This article was originally published in The Gray Sheet
Executive Summary
Emerging genetic test firm Allegro Diagnostics is a small fish poised to enter uncertain waters, but the lack of concrete guidelines on FDA regulation of in vitro diagnostic multivariate index assays (IVDMIA) isn't discouraging the company from seeking market entry
You may also be interested in...
FDA Genetic Test Oversight Is On The Rise, But How Far Can It Go?
It looks increasingly likely that FDA will play a larger role in genetic test oversight, though policymakers may soon have to decide just how much more the agency can and should do
FDA Takes Second Stab At Multivariate Diagnostic Oversight Guidelines
FDA cautiously moved ahead with its controversial plan to actively regulate certain laboratory-developed tests with the release of a revised 1draft guidance document July 24
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.